Staar Surgical Shares Up 62% As Investors Glimpse ICL Clinical Data
This article was originally published in The Gray Sheet
Executive Summary
Anticipation of strong three-year follow-up data on Staar Surgical's ICL phakic implants helped push the firm's stock up 61.5% in March
You may also be interested in...
Staar Surgical ICL
PMA for implantable contact lenses to treat myopia granted expedited review status, Staar Surgical announces July 1. The firm submitted the final portion of its application to FDA May 8 (1"The Gray Sheet" April 7, 2003, p. 24). FDA's Ophthalmic Devices Panel will review the ICL later this year, Staar says...
Staar Surgical ICL
PMA for implantable contact lenses to treat myopia granted expedited review status, Staar Surgical announces July 1. The firm submitted the final portion of its application to FDA May 8 (1"The Gray Sheet" April 7, 2003, p. 24). FDA's Ophthalmic Devices Panel will review the ICL later this year, Staar says...
Staar’s ICL Panel Review In Sight; Three-Year Data Will Support PMA
Staar Surgical's ICL collamer phakic intraocular implant will be reviewed by FDA's Ophthalmic Devices Panel May 23